Compared to the placebo, which was given to a further 182 participants who also had lupus, the authors say anifrolumab produced a statistically significant and clinically-meaningful reduction in the disease.

另外182名红斑狼疮患者则服用安慰剂。作者说与安慰剂相比，anifrolumab在统计学上显著降低了红斑狼疮疾病活动度，具有重大临床意义。

After 52 weeks, not only only did this drug reduce autoimmune activity in the relevant organs of many of the treated patients, it also reduced the rate of flare-ups - which include fever, painful joints, fatigue and rashes - and lessened the need for steroids.

52周后，这种药物不仅减少了患者相关器官的自身免疫活动，还减少了新症状的爆发，包括发烧、关节疼痛、疲劳和皮疹等，减少了患者对类固醇的使用需求。

"There is now a strong body of evidence demonstrating the benefit of anifrolumab, and we look forward to bringing this potential new medicine to patients with systemic lupus erythematosus as soon as possible," says Mene Pangalos, the executive vice president of BioPharmaceutical R&D.

梅内·潘加洛斯，R&D生物制药的执行副总裁说，“现在有很多强有力的证据证明了anifrolumab的疗效，我们期待尽快将这种潜在的新药带给系统性红斑狼疮患者。”

【医学界新进展：绝症红斑狼疮或许将能被治疗】相关文章：

★ 流体饮食或能治愈糖尿病

★ 意科学家因强震前辟谣被控过失杀人

★ 职业电竞选手其实是在吃青春饭

★ 威廉大婚引无限商机 女王手提袋热销

★ 《饥饿游戏》前传小说明年出版 狮门计划拍成电影

★ 语言学学士教你背单词

★ 真的很严格！原来英王室小公主和小王子是这么养成的……

★ 《权力的游戏》在印度也很火,原因尴尬

★ 28岁前应该尽早知道的16个道理

★ 一年之中有两个儿童节?